SCNI
Scinai Immunotherapeutics Ltd.
Biotechnology
Market Cap$715K
5Y Perf.-100.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
SCNI vs MNOV
Revenue, margins, valuation, and 5-year total return — side by side.
MNOV
MediciNova, Inc.
Biotechnology
Market Cap$70M
5Y Perf.-73.2%
SCNI vs MNOV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SCNI | MNOV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $715K | $70M |
| Revenue (TTM) | $1M | $410K |
| Net Income (TTM) | $4M | $-12M |
| Gross Margin | -147.0% | 7.6% |
| Operating Margin | -7.4% | -32.4% |
| Total Debt | $2M | $194K |
| Cash & Equiv. | $2M | $31M |
SCNI vs MNOV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SCNI
MNOV
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Scinai Immunotherap… (SCNI) | 100 | 0.0 | -100.0% |
| MediciNova, Inc. (MNOV) | 100 | 26.8 | -73.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SCNI vs MNOV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SCNI leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. MediciNova, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SCNI
Scinai Immunotherapeutics Ltd.
The Growth Leader
SCNI carries the broadest edge in this set and is the clearest fit for growth and quality.
- 99.2% revenue growth vs MNOV's -8.8%
- 356.7% margin vs MNOV's -29.3%
- 33.1% ROA vs MNOV's -26.3%, ROIC -60.1% vs -85.5%
Best for: growth and quality
MNOV
MediciNova, Inc.
The Income Pick
MNOV is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.31
- EPS growth -4.3%
- -80.1% 10Y total return vs SCNI's -99.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SCNI | 99.2% revenue growth vs MNOV's -8.8% |
| Quality / Margins | SCNI | 356.7% margin vs MNOV's -29.3% |
| Stability / Safety | MNOV | Beta 0.31 vs SCNI's 1.67, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MNOV | -4.0% vs SCNI's -80.6% |
| Efficiency (ROA) | SCNI | 33.1% ROA vs MNOV's -26.3%, ROIC -60.1% vs -85.5% |
SCNI vs MNOV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
SCNI vs MNOV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMNOVLAGGINGSCNI
SCNIScinai Immunotherapeu…
2leads
MNOVMediciNova, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs SCNIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SCNI4/5
Valuation MetricsMultiples, price ratios, and targets
SCNI2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MNOV5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MNOV6/6
Risk & VolatilityBeta, volatility, and downside exposure
MNOV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SCNI leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SCNI is the larger business by revenue, generating $1M annually — 2.8x MNOV's $409,657. SCNI is the more profitable business, keeping 3.6% of every revenue dollar as net income compared to MNOV's -29.3%.
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $409,657 |
| EBITDAEarnings before interest/tax | -$7M | -$13M |
| Net IncomeAfter-tax profit | $4M | -$12M |
| Free Cash FlowCash after capex | -$6M | -$10M |
| Gross MarginGross profit ÷ Revenue | -147.0% | +7.6% |
| Operating MarginEBIT ÷ Revenue | -7.4% | -32.4% |
| Net MarginNet income ÷ Revenue | +3.6% | -29.3% |
| FCF MarginFCF ÷ Revenue | -5.0% | -23.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +36.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +66.7% | +4.7% |
SCNI leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
SCNI leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| Market CapShares × price | $714,770 | $70M |
| Enterprise ValueMkt cap + debt − cash | $1M | $40M |
| Trailing P/EPrice ÷ TTM EPS | -0.15x | -5.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.55x | 171.21x |
| Price / BookPrice ÷ Book value/share | 0.16x | 1.69x |
| Price / FCFMarket cap ÷ FCF | — | — |
SCNI leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
MNOV leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
SCNI delivers a 45.8% return on equity — every $100 of shareholder capital generates $46 in annual profit, vs $-29 for MNOV. MNOV carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to SCNI's 0.28x. On the Piotroski fundamental quality scale (0–9), MNOV scores 3/9 vs SCNI's 2/9, reflecting mixed financial health.
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +45.8% | -28.9% |
| ROA (TTM)Return on assets | +33.1% | -26.3% |
| ROICReturn on invested capital | -60.1% | -85.5% |
| ROCEReturn on capital employed | -69.6% | -28.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.28x | 0.00x |
| Net DebtTotal debt minus cash | $606,000 | -$31M |
| Cash & Equiv.Liquid assets | $2M | $31M |
| Total DebtShort + long-term debt | $2M | $194,331 |
| Interest CoverageEBIT ÷ Interest expense | 3.35x | — |
MNOV leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MNOV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNOV five years ago would be worth $3,488 today (with dividends reinvested), compared to $19 for SCNI. Over the past 12 months, MNOV leads with a -4.0% total return vs SCNI's -80.6%. The 3-year compound annual growth rate (CAGR) favors MNOV at -13.2% vs SCNI's -69.6% — a key indicator of consistent wealth creation.
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -25.6% | +7.5% |
| 1-Year ReturnPast 12 months | -80.6% | -4.0% |
| 3-Year ReturnCumulative with dividends | -97.2% | -34.7% |
| 5-Year ReturnCumulative with dividends | -99.8% | -65.1% |
| 10-Year ReturnCumulative with dividends | -99.9% | -80.1% |
| CAGR (3Y)Annualised 3-year return | -69.6% | -13.2% |
MNOV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MNOV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MNOV is the less volatile stock with a 0.31 beta — it tends to amplify market swings less than SCNI's 1.67 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNOV currently trades 73.0% from its 52-week high vs SCNI's 8.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.67x | 0.31x |
| 52-Week HighHighest price in past year | $6.18 | $1.96 |
| 52-Week LowLowest price in past year | $0.45 | $1.17 |
| % of 52W HighCurrent price vs 52-week peak | +8.8% | +73.0% |
| RSI (14)Momentum oscillator 0–100 | 45.2 | 55.8 |
| Avg Volume (50D)Average daily shares traded | 4.1M | 47K |
MNOV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | SCNIScinai Immunother… | MNOVMediciNova, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MNOV leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). SCNI leads in 2 (Income & Cash Flow, Valuation Metrics).
Best OverallMediciNova, Inc. (MNOV)Leads 3 of 6 categories
Loading custom metrics...
SCNI vs MNOV: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — SCNI or MNOV?
Over the past 5 years, MediciNova, Inc.
(MNOV) delivered a total return of -65. 1%, compared to -99. 8% for Scinai Immunotherapeutics Ltd. (SCNI). Over 10 years, the gap is even starker: MNOV returned -80. 1% versus SCNI's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — SCNI or MNOV?
By beta (market sensitivity over 5 years), MediciNova, Inc.
(MNOV) is the lower-risk stock at 0. 31β versus Scinai Immunotherapeutics Ltd. 's 1. 67β — meaning SCNI is approximately 440% more volatile than MNOV relative to the S&P 500. On balance sheet safety, MediciNova, Inc. (MNOV) carries a lower debt/equity ratio of 0% versus 28% for Scinai Immunotherapeutics Ltd. — giving it more financial flexibility in a downturn.
03Which is growing faster — SCNI or MNOV?
On earnings-per-share growth, the picture is similar: MediciNova, Inc.
grew EPS -4. 3% year-over-year, compared to -160. 0% for Scinai Immunotherapeutics Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — SCNI or MNOV?
Scinai Immunotherapeutics Ltd.
(SCNI) is the more profitable company, earning -633. 6% net margin versus -29. 3% for MediciNova, Inc. — meaning it keeps -633. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SCNI leads at -575. 3% versus -32. 4% for MNOV. At the gross margin level — before operating expenses — MNOV leads at 7. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SCNI or MNOV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SCNI or MNOV better for a retirement portfolio?
For long-horizon retirement investors, MediciNova, Inc.
(MNOV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 31)). Scinai Immunotherapeutics Ltd. (SCNI) carries a higher beta of 1. 67 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNOV: -80. 1%, SCNI: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SCNI and MNOV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SCNI is a small-cap high-growth stock; MNOV is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.